A new report indicates the potential future impact of the USA’s CBD industry being left in limbo with regard to Food and Drug Administration (FDA) regulations.
While cannabidiol (CBD) has been legal in the USA since the signing of the 2018 Farm Bill into law, the FDA is yet to implement regulations concerning its use as a . This isn’t good for the industry or consumer.
A forecast from looks at two scenarios out to 2027much-needed reform it
Brightfield says this year. And i FDA reformsit s sales a whopping
“,” says the firm.
But wBrightfield expects will 7 by 2027
says Brightfield. “,” “
Consumers and businesses are justified to be hesitant in buying and stocking CBD products. A number of studies shows there continues to be quality control and labelling issues – and that’s bad for all stakeholders.
Currently, the FDA has approved only one CBD product, which is a prescription drug product to treat seizures and one other condition. The Administration continues to assert that it is currently illegal to market cannabidiol by adding it to a food or labeling it as a dietary supplement, based on a claimed lack of safety data. It has sent out plenty of warning letters to companies that do.
Some companies get around FDA-related issues in creative ways. For example, by incorporating Brightfield notes in the USA, but c beverages “ ”